Wall Street analysts expect Chimerix Inc (NASDAQ:CMRX) to report sales of $1.93 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Chimerix’s earnings. The highest sales estimate is $3.93 million and the lowest is $800,000.00. Chimerix reported sales of $790,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 144.3%. The company is expected to issue its next earnings results on Monday, May 6th.

On average, analysts expect that Chimerix will report full year sales of $6.85 million for the current year, with estimates ranging from $3.80 million to $11.10 million. For the next fiscal year, analysts expect that the firm will post sales of $20.08 million, with estimates ranging from $9.23 million to $26.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Chimerix.

Chimerix (NASDAQ:CMRX) last issued its earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.07. Chimerix had a negative return on equity of 35.97% and a negative net margin of 951.77%.

Several equities analysts have recently weighed in on the company. Citigroup lowered their price target on Chimerix from $4.25 to $2.00 and set a “neutral” rating on the stock in a report on Wednesday, March 6th. Zacks Investment Research raised Chimerix from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a report on Friday, February 22nd. HC Wainwright reissued a “buy” rating on shares of Chimerix in a report on Wednesday, February 6th. Finally, ValuEngine raised Chimerix from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $5.06.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Citigroup Inc. lifted its holdings in shares of Chimerix by 81.2% during the 4th quarter. Citigroup Inc. now owns 19,570 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 8,771 shares during the period. SG Americas Securities LLC bought a new position in shares of Chimerix during the 4th quarter valued at $26,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Chimerix by 3.8% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 303,395 shares of the biopharmaceutical company’s stock worth $780,000 after purchasing an additional 11,050 shares during the period. HRT Financial LLC bought a new position in Chimerix in the 4th quarter worth $40,000. Finally, Pitcairn Co. bought a new position in Chimerix in the 4th quarter worth $42,000. 73.65% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ CMRX traded up $0.13 during midday trading on Friday, hitting $1.98. 1,026,230 shares of the stock traded hands, compared to its average volume of 384,435. The stock has a market capitalization of $103.33 million, a price-to-earnings ratio of -1.38 and a beta of 1.34. Chimerix has a one year low of $1.74 and a one year high of $5.85.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

See Also: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.